AU2018235031B2 - Anti-PAR2 antibodies and uses thereof - Google Patents

Anti-PAR2 antibodies and uses thereof Download PDF

Info

Publication number
AU2018235031B2
AU2018235031B2 AU2018235031A AU2018235031A AU2018235031B2 AU 2018235031 B2 AU2018235031 B2 AU 2018235031B2 AU 2018235031 A AU2018235031 A AU 2018235031A AU 2018235031 A AU2018235031 A AU 2018235031A AU 2018235031 B2 AU2018235031 B2 AU 2018235031B2
Authority
AU
Australia
Prior art keywords
prt
seq
antibody
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018235031A
Other languages
English (en)
Other versions
AU2018235031A1 (en
Inventor
Claire Dobson
David FAIRMAN
Ian GURRELL
Philip Newton
Sadhana PODICHETTY
Peter Thornton
Richard Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2018235031A1 publication Critical patent/AU2018235031A1/en
Application granted granted Critical
Publication of AU2018235031B2 publication Critical patent/AU2018235031B2/en
Priority to AU2021257983A priority Critical patent/AU2021257983B2/en
Priority to AU2025203947A priority patent/AU2025203947A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2018235031A 2017-03-16 2018-03-16 Anti-PAR2 antibodies and uses thereof Active AU2018235031B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021257983A AU2021257983B2 (en) 2017-03-16 2021-10-27 Anti-par2 antibodies and uses thereof
AU2025203947A AU2025203947A1 (en) 2017-03-16 2025-05-27 Anti-PAR2 antibodies and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762472462P 2017-03-16 2017-03-16
US62/472,462 2017-03-16
US201862637766P 2018-03-02 2018-03-02
US62/637,766 2018-03-02
PCT/EP2018/056776 WO2018167322A1 (en) 2017-03-16 2018-03-16 Anti-par2 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021257983A Division AU2021257983B2 (en) 2017-03-16 2021-10-27 Anti-par2 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2018235031A1 AU2018235031A1 (en) 2019-10-31
AU2018235031B2 true AU2018235031B2 (en) 2021-08-12

Family

ID=61827709

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018235031A Active AU2018235031B2 (en) 2017-03-16 2018-03-16 Anti-PAR2 antibodies and uses thereof
AU2021257983A Active AU2021257983B2 (en) 2017-03-16 2021-10-27 Anti-par2 antibodies and uses thereof
AU2025203947A Pending AU2025203947A1 (en) 2017-03-16 2025-05-27 Anti-PAR2 antibodies and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021257983A Active AU2021257983B2 (en) 2017-03-16 2021-10-27 Anti-par2 antibodies and uses thereof
AU2025203947A Pending AU2025203947A1 (en) 2017-03-16 2025-05-27 Anti-PAR2 antibodies and uses thereof

Country Status (30)

Country Link
US (4) US10836822B2 (cg-RX-API-DMAC7.html)
EP (2) EP4681726A3 (cg-RX-API-DMAC7.html)
JP (3) JP7222901B2 (cg-RX-API-DMAC7.html)
KR (1) KR102711884B1 (cg-RX-API-DMAC7.html)
CN (1) CN110446720B (cg-RX-API-DMAC7.html)
AU (3) AU2018235031B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019018752A2 (cg-RX-API-DMAC7.html)
CA (1) CA3055251A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002626A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019010975A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190417A (cg-RX-API-DMAC7.html)
DK (1) DK3596125T3 (cg-RX-API-DMAC7.html)
ES (1) ES3056721T3 (cg-RX-API-DMAC7.html)
FI (1) FI3596125T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251643T1 (cg-RX-API-DMAC7.html)
IL (1) IL269134B2 (cg-RX-API-DMAC7.html)
LT (1) LT3596125T (cg-RX-API-DMAC7.html)
MA (1) MA49886A (cg-RX-API-DMAC7.html)
MX (1) MX2019010802A (cg-RX-API-DMAC7.html)
NZ (1) NZ757915A (cg-RX-API-DMAC7.html)
PH (1) PH12019502087A1 (cg-RX-API-DMAC7.html)
PL (1) PL3596125T3 (cg-RX-API-DMAC7.html)
PT (1) PT3596125T (cg-RX-API-DMAC7.html)
RS (1) RS67581B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201908056QA (cg-RX-API-DMAC7.html)
SI (1) SI3596125T1 (cg-RX-API-DMAC7.html)
TW (1) TWI788332B (cg-RX-API-DMAC7.html)
UA (1) UA125757C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018167322A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201906004B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
MA49886A (fr) * 2017-03-16 2020-06-24 Medimmune Ltd Anticorps anti-par2 et leurs utilisations
US12214216B1 (en) 2019-10-16 2025-02-04 Helen Feng Photon enhanced bone growth system and method
AU2021328375A1 (en) * 2020-08-18 2023-04-13 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
GB202204159D0 (en) 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
AU2024212070A1 (en) 2023-01-25 2025-07-31 Medimmune Limited Migraine therapy
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025191185A1 (en) 2024-03-15 2025-09-18 Domain Therapeutics Azine-based compounds as par-2 inhibitors and therapeutic uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031695A1 (en) * 2009-09-09 2011-03-17 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human protease-activated receptor-2
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20070053911A1 (en) * 2003-03-11 2007-03-08 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8440627B2 (en) * 2004-11-04 2013-05-14 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
AR070911A1 (es) * 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
WO2010017086A1 (en) * 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Effectors of par-2 activation and their use in the modulation of inflammation
HUE051130T2 (hu) * 2008-08-07 2021-03-01 Idexx Lab Inc Eljárások szimmetrikus dimetilarginin kimutatására
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
NZ704771A (en) * 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
EP3160996B1 (en) 2014-06-30 2022-06-08 Merck Patent GmbH Anti-tnfa antibodies with ph-dependent antigen binding
MA49886A (fr) * 2017-03-16 2020-06-24 Medimmune Ltd Anticorps anti-par2 et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031695A1 (en) * 2009-09-09 2011-03-17 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human protease-activated receptor-2
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING

Also Published As

Publication number Publication date
CL2019002626A1 (es) 2019-12-06
US20210061905A1 (en) 2021-03-04
US20260078180A1 (en) 2026-03-19
KR102711884B1 (ko) 2024-10-02
BR112019018752A2 (pt) 2020-05-05
JP2025102812A (ja) 2025-07-08
UA125757C2 (uk) 2022-06-01
ES3056721T3 (en) 2026-02-24
JP2020509762A (ja) 2020-04-02
CR20190417A (es) 2019-12-06
HRP20251643T1 (hr) 2026-02-13
SI3596125T1 (sl) 2026-01-30
IL269134B2 (en) 2024-07-01
ZA201906004B (en) 2025-10-29
CN110446720B (zh) 2023-09-12
TWI788332B (zh) 2023-01-01
JP2023055895A (ja) 2023-04-18
CO2019010975A2 (es) 2019-10-21
CN110446720A (zh) 2019-11-12
KR20190129925A (ko) 2019-11-20
MX2019010802A (es) 2019-10-30
CA3055251A1 (en) 2018-09-20
DK3596125T3 (da) 2025-12-22
WO2018167322A1 (en) 2018-09-20
PH12019502087A1 (en) 2020-03-09
EP4681726A2 (en) 2026-01-21
IL269134B1 (en) 2024-03-01
EP3596125B1 (en) 2025-11-19
AU2025203947A9 (en) 2026-03-19
LT3596125T (lt) 2026-01-26
FI3596125T3 (fi) 2025-12-29
EP3596125A1 (en) 2020-01-22
TW201843176A (zh) 2018-12-16
NZ757915A (en) 2023-05-26
PT3596125T (pt) 2025-11-27
JP7222901B2 (ja) 2023-02-15
IL269134A (en) 2019-11-28
AU2025203947A1 (en) 2025-06-19
US10836822B2 (en) 2020-11-17
EP4681726A3 (en) 2026-04-01
PL3596125T3 (pl) 2026-02-09
US11591389B2 (en) 2023-02-28
RS67581B1 (sr) 2026-01-30
AU2021257983A1 (en) 2021-11-25
SG11201908056QA (en) 2019-09-27
AU2021257983B2 (en) 2025-02-27
MA49886A (fr) 2020-06-24
AU2018235031A1 (en) 2019-10-31
US20230242639A1 (en) 2023-08-03
US20180305450A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
AU2021257983B2 (en) Anti-par2 antibodies and uses thereof
TW202019966A (zh) 雙特異性抗－ＢＣＭＡｘ抗－ＣＤ３抗體及其用途
US20240309100A1 (en) Anti-Trkb Monoclonal Antibodies And Methods Of Use
RS56368B1 (sr) Antitela na humani gdf8
JP2016501892A (ja) 治療用ｃｄ４７抗体
CA3094286A1 (en) Gipr antibody and its fusion protein with glp-1, and pharmaceutical composition and application thereof
US12110336B2 (en) Method for treating a neurodegenerative disease by administering an anti-cellular prion protein (PrPc) antibody
CA3212049A1 (en) Human antibodies to artemin and methods of use thereof
EA044850B1 (ru) Антитела к par2 и пути их применения
BR122025022029A2 (pt) Anticorpos anti-par2 ou seu fragmento de ligação ao antígeno, ácido nucleico, vetor, célula hospedeira, composição e seus usos
US20260000758A1 (en) Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
US20250043017A1 (en) BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF
TW202519559A (zh) 雙特異性PD-L1xCD28抗體及其使用方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)